Anzeige

Archive

The Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas receptor axis: A potential target for treating thrombotic diseases

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Topic:

Theme Issue
Scoring in thrombotic cardiovascular disease

DOI: https://doi.org/10.1160/TH12-06-0396
Issue: 2012: 108/6 (Dec) pp. 1009–1248
Pages: 1089-1096

The Angiotensin-Converting Enzyme 2/Angiotensin-(1–7)/Mas receptor axis: A potential target for treating thrombotic diseases

R. A. Fraga-Silva (1), D. G. Da Silva (1), F. Montecucco (2, 3), F. Mach (2), N. Stergiopulos (1), R. F. da Silva (1, 4), R. A. S. Santos (4)

(1) Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; (2) Division of Cardiology, Geneva University Hospitals, Faculty of Medicine, Foundation for Medical Researches, Geneva, Switzerland; (3) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy; (4) National Institute of Science and Technology in Nanobiopharmaceutics, Department of Physiology and Biophysics, Biological Science Institute, Federal University of Minas Gerais, Brazil

Keywords

thrombosis, Platelet, Angiotensin-(1–7), Angiotensin Converting Enzyme 2, Receptor Mas

Summary

Despite many therapeutic advances leading to increasingly effective drug treatments, thrombotic events (such as ischaemic stroke, pulmonary embolism, deep venous thrombosis and acute myocardial infarction) still represent a major worldwide cause of morbidity and mortality. Remarkable effort has been made to identify new drug targets. There is growing evidence indicating that the recently described counter-regulator axis of the renin-angiotensin system (RAS), composed of Angiotensin-Converting Enzyme 2 (ACE2), Angiotensin-(1–7) and the Mas receptor, has protective effects against thrombosis. In addition, it could be considered as a promising target for treating or preventing this disease. In this narrative review, we focused on the recent findings of the role of the ACE2/Angiotensin-(1–7)/Mas axis on the haemostatic process and its therapeutic potential.

You may also be interested in...

1.
Charalambos Tymvios 1, Sarah Jones 1, Christopher Moore 1, Simon C. Pitchford 1, Clive P. Page 2, Michael Emerson1

Thromb Haemost 2008 99 2: 435-440

https://doi.org/10.1160/TH07-07-0479

2.
Jong-Shyan Wang1 , Hsiang-Ling Yen 1 , Chuen-Mao Yang2

Thromb Haemost 2006 95 3: 490-498

https://doi.org/10.1160/TH05-09-0646

3.
Thienopyridines and direct oral inhibitors

J.-P. Collet (1), G. Montalescot (1)

Hämostaseologie 2009 29 4: 339-348